U.S., Aug. 6 -- ClinicalTrials.gov registry received information related to the study (NCT07746583) titled 'A Study of Guselkumab Given After Ustekinumab in Participants With Moderate to Severe Psoria... और पढ़ें
Singapore, Aug. 6 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 3-Arm Study to Investigate the Safety and ... और पढ़ें
Singapore, Aug. 6 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 3-Arm Study to Investigate the Safety and ... और पढ़ें
U.S., Aug. 6 -- ClinicalTrials.gov registry received information related to the study (NCT07748013) titled 'Impact of Harp Therapy on Behavioral Disorders in Nursing Home Residents With Neurodegenerat... और पढ़ें
Singapore, Aug. 6 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 3-Arm Study to Investigate the Safety and ... और पढ़ें
Singapore, Aug. 6 -- The Health Sciences Authority received information related to the study titled 'A Phase 1, Randomized, Placebo-Controlled, Investigator and Participant Blinded, Single Ascending D... और पढ़ें
U.S., Aug. 6 -- ClinicalTrials.gov registry received information related to the study (NCT07748078) titled 'Snoezelen Therapy in Adults With Alcohol Dependence and Adults With Schizophrenia' on July 2... और पढ़ें
Singapore, Aug. 6 -- The Health Sciences Authority received information related to the study titled 'A Global Multicenter, Open Label, Randomized Phase 3 Registrational Study of Olverembatinib Combine... और पढ़ें
Singapore, Aug. 6 -- The Health Sciences Authority received information related to the study titled ''Establishing the role of mitomycin C and systemic non-steroidal anti-inflammatory drugs in the pos... और पढ़ें
Singapore, Aug. 6 -- The Health Sciences Authority received information related to the study titled 'IZABRIGHT-Lung01: A Randomized, Open-label, Phase 2/3 Study of Izalontamab Brengitecan (BMS-986507)... और पढ़ें